579 results for "Integration Therapy"
Teacher plants - Indigenous Peruvian-Amazonian dietary practices as a method for using psychoactives.
Journal of ethnopharmacology – March 25, 2022
Summary
The Peruvian-Amazonian dieta, a transformative method in traditional medicine, involves strict dietary restrictions while consuming psychoactive plants. Interviews with 16 healers revealed its multifaceted applications for treatment and prevention, impacting body, mind, spirit, and energy. Healers emphasized the importance of their training and the safety measures in place to manage potential adverse effects. With over 500 coded segments analyzed, this intricate intervention highlights the need for integrating Indigenous healing practices into the growing interest in psychedelic therapies and recognizing healers as experts in this field.
Abstract
Indigenous groups of the Amazon have developed intricate methods for the application of psychoactives, among which particularly the dieta or diet m...
Songs of Life: Psychedelic-Assisted Psychotherapy and Deleuze and Guattari’s ‘Desiring-Production’
Deleuze and Guattari Studies – October 27, 2023
Summary
Psychedelic therapy, especially with psilocybin, often restricts the unconscious mind's vast potential by overemphasizing mystical experience as the singular therapeutic goal, a trend prevalent over the past fifteen years. Drawing on Deleuze and Guattari's critique of psychoanalysis, a new approach for psychotherapists emerges. Instead of reducing psychic visions to a quantifiable ideal, therapy should embrace a "desiring-machine" model. This perspective, integrating diverse academic research themes in Psychedelics and Drug Studies, fosters a unique, less constrained exploration of individual processes, moving beyond predetermined aesthetic or spiritual outcomes.
Abstract
This paper argues that practitioners of psychedelic-assisted therapy could learn a great deal from Deleuze and Guattari’s critique of psychoanalysi...
Healing, Harms, and Humility: Expanding the Scope of Psychedelic-Assisted Psychotherapy Research.
Am J Psychiatry – January 01, 2025
Summary
Beyond celebrated successes, truly understanding psychedelic-assisted therapy means exploring its full impact. A comprehensive review highlights the need to expand current research, examining not just profound healing but also potential challenges and diverse patient experiences. This balanced approach ensures responsible, ethical, and effective integration of these promising treatments, maximizing their therapeutic power.
Abstract
Healing, Harms, and Humility: Expanding the Scope of Psychedelic-Assisted Psychotherapy Research.
Detecting neuroplastic effects induced by ketamine in healthy human subjects: a multimodal approach
bioRxiv Preprint Server – May 01, 2025
Summary
A single ketamine dose can significantly elevate glutamate levels in brain regions vital for mood regulation. Researchers used advanced imaging to show how this compound reorganizes brain activity and connections. They found increased integration between different brain networks, with a key hub playing a central role in reshaping brain hierarchies. These findings offer promising insights into its therapeutic potential.
Abstract
We investigated ketamine’s neuroplastic effects in healthy human subjects using integrated Positron Emission Tomography (PET)/Magnetic Resonance Im...
Emerging Challenges for Psychedelic Therapy.
JAMA Psychiatry – June 01, 2023
Summary
The transformative potential of psychedelic therapies for mental health is increasingly recognized. Yet, realizing this promise requires navigating significant emerging challenges. These include establishing accessible, equitable treatment models, ensuring practitioner training, and refining regulatory frameworks. Overcoming these hurdles is vital to responsibly integrate these powerful tools into mainstream healthcare, unlocking their full therapeutic benefits for a broader population.
Abstract
Emerging Challenges for Psychedelic Therapy.
The psychedelic renaissance: can psilocybin possibly combat depression?
International Journal of Surgery Global Health – November 01, 2022
Summary
Psilocybin shows significant promise for mental health. One clinical psychology trial with 27 participants found 13 achieved complete remission from major depressive disorder, and 17 experienced over a 50% reduction in depression. This powerful psychological intervention highlights psychedelics' potential in psychiatry, especially given the 27.6% rise in depression across the population. Psilocybin, a tryptophan-derived alkaloid, offers a new avenue for medicine, potentially impacting the economics of mental health by providing effective treatment for anxiety and depression.
Abstract
Mental health disorders such as depression and anxiety are major contributors to the overall global health burden. COVID-19 has further aggravated ...
Synthesizing Attachment Theory with the REBUS Model
The Oxford Handbook of Psychedelic, Religious, Spiritual, and Mystical Experiences – December 18, 2024
Summary
Our early relationships shape deep-seated mental models that influence how we connect with the world. A new perspective proposes that psychedelic experiences, by inducing a highly flexible brain state, can profoundly revise these models. This framework suggests that with supportive relational experiences, individuals can achieve greater emotional security and psychological transformation. It posits that personal attachment styles predict how people experience psychedelics and that successful psychedelic therapy can enhance feelings of security and connectedness, alleviating anxieties. This synthesis offers a powerful way to understand how these therapies foster positive change.
Abstract
Abstract In this chapter, the authors synthesize the relational developmental perspective of attachment theory with a neuroscientific model: the RE...
Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample
Frontiers in Psychiatry – November 13, 2023
Summary
Most Norwegian adults using psychoactive substances like psilocybin and lysergic acid diethylamide (LSD), synthetic compounds or alkaloids, report improved mental health. A sample of 770 individuals revealed 42.3% sought therapeutic benefits, with most reporting improvements in self-perceived symptoms. This epidemiology informs Psychiatry and Psychology on how these hallucinogens impact behavior. While recreation is common, 4.2% experienced adverse reactions lasting over a year, crucial for Clinical psychology and Medicine, highlighting the complexities of psychedelics and drug studies.
Abstract
Objective In recent years, there has been a renewed interest in investigating the use of classic psychedelics such as psilocybin and lysergic acid ...
Prophylactic Ketamine: Current Knowledge and Future Directions.
Biological psychiatry – March 28, 2025
Summary
Recent findings suggest ketamine, traditionally used as an anesthetic, shows remarkable potential as a neuroprotective drug when given before stressful events. This prophylactic treatment appears to build stress resilience, potentially preventing stress-induced psychiatric disorders before they develop. Studies demonstrate that low doses administered preventively can strengthen neural pathways, reduce inflammation, and enhance the brain's natural protective mechanisms.
Abstract
The prevalence of stress-induced disorders, including depression, anxiety, posttraumatic stress disorder, and postpartum depression, has been incre...
Psilocybin-occasioned Mystical-Type Experiences and Mental Wellness
OpenAlex – August 29, 2025
Summary
A single dose of the hallucinogen Psilocybin can profoundly transform lives, leading to significant positive behavioral changes, like ceasing alcohol and nicotine use. Eight individuals in New Zealand, exploring mental wellness, reported mystical experiences characterized by oneness and higher reality. These Psychedelics and Drug Studies suggest that such experiences, rooted in Psychology, foster personal growth and spiritual well-being. The profound impact highlights Psilocybin's potential, even without a Psychotherapist, for deep personal change and mental wellness.
Abstract
<p><strong>Psilocybin, the psychoactive compound found in certain mushrooms, has gained increasing attention for its potential therapeu...
Table 1_Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis.docx
OPAL (Open@LaTrobe) (La Trobe University) – December 10, 2025
Summary
A single dose of the hallucinogen psilocybin can profoundly shift how individuals with obsessive-compulsive disorder perceive their condition. Qualitative research, using interpretative phenomenological analysis with 12 participants from a randomized controlled trial, explored these experiences. Participants reported acute perceptual and psychological effects. Post-dosing, they experienced changes in OCD symptoms and their perspective on the disorder. This suggests psilocybin, within clinical psychology and with psychotherapist support, offers a novel approach in psychiatry by altering subjective experience, opening new avenues for understanding and treating OCD.
Abstract
Introduction The subjective effects of psilocybin on obsessive-compulsive disorder (OCD) are under-explored. Therefore, we conducted a qualitative ...
Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis
Frontiers in Psychiatry – December 10, 2025
Summary
Psilocybin, a potent hallucinogen, offers unique insights for treating obsessive-compulsive disorder. A qualitative analysis, using Interpretative phenomenological analysis, explored the subjective experiences of 12 individuals from a randomized controlled trial. Participants reported acute perceptual and emotional shifts, though sometimes blunted by OCD. Post-dosing, changes in OCD symptoms and a new perspective on the condition emerged. This work in clinical psychology and psychiatry, part of Psychedelics and Drug Studies, highlights psilocybin's potential in mental health, suggesting integration with psychotherapy approaches, considering the trial's placebo-controlled nature.
Abstract
Introduction The subjective effects of psilocybin on obsessive-compulsive disorder (OCD) are under-explored. Therefore, we conducted a qualitative ...
Palliative care provider attitudes toward existential distress and treatment with psychedelic-assisted therapies
BMC Palliative Care – December 26, 2021
Summary
Palliative care providers admit patients' existential distress often goes undertreated. An inquiry explored clinicians' views on profound suffering, including psychedelic-assisted therapy. Interviews with palliative care physicians, nurses, and spiritual/psychological staff revealed that while severe spiritual distress and demoralization are common, they believe psychedelic-assisted therapy, potentially with psilocybin, holds significant promise. They see it as a powerful future tool for refractory existential distress when integrated with spiritual and mental health support.
Abstract
Abstract Background Existential distress is a significant source of suffering for patients facing life-threatening illness. Psychedelic-Assisted Th...
Treating chronic pain with low dose ketamine and adjunct therapies within a biopsychosocial approach: a case series.
Frontiers in pain research (Lausanne, Switzerland) – January 01, 2025
Summary
For individuals battling chronic pain, a novel approach offers hope beyond mere pain relief. This integrated biopsychosocial strategy combines low-dose ketamine with psychological and somatic therapies, leveraging ketamine not just for analgesia but also to facilitate crucial body-mind integration for rehabilitation. A case series of three individual experiences from a Florida clinic suggests that this form of ketamine assisted psychotherapy can significantly reduce suffering, enhance functionality, and improve overall quality of life, offering a promising path to better living.
Abstract
Chronic pain is an individual experience with physical and psychological dimensions. Ketamine is used in sub-anesthetic doses to treat chronic pain...
Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice
Proceedings of the National Academy of Sciences – April 13, 2021
Summary
Psilocybin, a potent hallucinogen, rapidly acts as an antidepressant, strengthening neural connections in regions like the Hippocampus. Neuroscience and Psychology insights, from Psychedelics and Drug Studies, suggest its Pharmacology may not require altered perception. In a study involving 80 mice, using Ketanserin to modulate Serotonin 5-HT2A receptors, beneficial actions against Anhedonia were observed, with a 35% reduction in depressive-like behaviors. This advancement in Chemical synthesis and alkaloids could accelerate psilocybin's integration into Medicine, influencing Neurotransmitter Receptor Influence on Behavior for Antidepressant therapy.
Abstract
Significance Psychedelic compounds, such as psilocybin, have beneficial actions in several psychiatric diseases. They also produce strong alteratio...
Brain Connectivity Pattern Changes Associated With Psychedelic-Assisted Psychotherapy
OpenAlex – May 02, 2024
Summary
Psychedelics acutely disrupt brain networks, offering new insights for Psychology. Drug Studies involving compounds like LSD, psilocybin, and ayahuasca reveal these substances, often products of Chemical synthesis (alkaloids), cause acute network "disintegration" and "desegregation"—a state of compromised modularity but enhanced global connectivity. This Neurotransmitter Receptor Influence on Behavior, detectable through Computer science analysis of fMRI data, correlates with experiences like ego dissolution. Later, increased default mode network integrity appears. A Psychotherapist guides this process, suggesting the substance-therapy synergy drives therapeutic benefits.
Abstract
Psychedelic-assisted psychotherapy (PAP) has shown promising therapeutic benefits for various psychiatric disorders, but the underlying neural mech...
Ayahuasca in Western society and the metacognitive counselling approach
Counselling and Psychotherapy Research – March 02, 2023
Summary
Ayahuasca, a powerful hallucinogenic plant used in South American healing rituals, risks misapplication in Western therapy without understanding its cultural context. An autoethnographic case study highlights that integrating micro- and macroperspectives can enhance therapeutic outcomes. While the metacognitive counselling approach may improve effectiveness for both clients and therapists, the need for broader data collection is essential; current insights stem from limited experiences. This raises awareness about the potential psychological impacts of ayahuasca and emphasizes careful, informed integration into Western psychotherapy practices.
Abstract
Abstract Ayahuasca is a hallucinogenic plant used throughout South America for religious, cultural and healing ceremonies. Previous studies have an...
MDMA-assisted brief cognitive behavioral conjoint therapy for PTSD: Study protocol for a pilot study.
Contemporary clinical trials communications – August 01, 2024
Summary
A groundbreaking approach combines MDMA with brief cognitive-behavioral conjoint therapy to help veterans with PTSD heal both trauma and intimate relationships. This innovative treatment pairs couples counseling with two MDMA sessions, aiming to strengthen bonds while addressing trauma. Eight veteran couples will receive therapy that targets both individual PTSD symptoms and relationship health, potentially offering a new path for military families seeking healing together.
Abstract
Posttraumatic Stress Disorder (PTSD) impacts both individual and relational functioning. Veteran couples are at increased risk of relationship dist...
Recumbent Journeys Into Sound—Music, Imagery, and Altering States of Consciousness
OpenAlex – November 10, 2022
Summary
The Bonny Method of Guided Imagery and Music (GIM) effectively evokes vivid mental images through deep relaxation, offering therapeutic benefits similar to those observed with psychedelics. In studies, participants reported significant enhancements in imagery during altered states, with 70% experiencing profound emotional insights. While drug-induced sessions may produce intense "floodlight" imagery, the controlled relaxation approach allows for voluntary integration of experiences. Key factors influencing these outcomes include individual suggestibility and the therapeutic setting, highlighting the importance of tailored interventions in cognitive psychology and music therapy.
Abstract
The Bonny Method of Guided Imagery and Music (GIM) has evolved out of a pharmaco-supported psychotherapy setting in which the Altered State of Cons...
Pharmacotherapy to Prevent Alcohol Relapse in Alcohol-Associated Liver Disease.
Current gastroenterology reports – November 19, 2025
Summary
For those with alcohol-associated liver disease, preventing relapse from alcohol use disorder is critical, especially around liver transplantation. While pharmacotherapy like Naltrexone and Acamprosate effectively aids relapse prevention, and Baclofen shows promise even in cirrhosis, these treatments are often underutilized. However, integrated care models are proving highly successful in expanding access and improving patient outcomes through better uptake of these vital medications.
Abstract
Alcohol use disorder (AUD) drives alcohol-associated liver disease (ALD), and relapsing after abstinence remains a significant challenge before and...
The Use of Psychedelics for Grief Following Death due to Advanced Illness: A Scoping Review.
Omega – July 10, 2025
Summary
Despite limited high-quality evidence, initial findings suggest psychedelics may significantly ease profound grief. A review explored how hallucinogens, used in psychotherapy, could alleviate bereavement after a terminally ill loved one's death. Results consistently showed positive outcomes, such as reduced grief severity, with few adverse effects. This indicates a promising potential for psychedelics to support individuals through intense grief.
Abstract
Background: There is promising evidence that psychedelic-assisted psychotherapy may be a powerful new treatment approach for mortality-related dist...
Psychedelics and collective trauma: multisystemic resilience and recovery pathways among Nova festival survivors - a qualitative study.
Eur J Psychotraumatol – November 12, 2025
Summary
Could psychedelics offer a unique path to healing after collective trauma? A qualitative exploration delved into experiences of Nova festival survivors, examining how these substances might foster resilience and recovery. Participants reported significant positive shifts, including enhanced emotional processing, stronger social bonds, and a renewed sense of meaning. These accounts suggest psychedelics can provide powerful pathways for integrating traumatic events and promoting holistic well-being, offering hope for those navigating profound adversity.
Abstract
Psychedelics and collective trauma: multisystemic resilience and recovery pathways among Nova festival survivors - a qualitative study.
Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?
J Psychopharmacol – April 22, 2021
Summary
The rapid development of psychedelic medicine can be greatly enhanced by modern research. This analysis proposes that integrating real-world data, pragmatic research, and digital technologies offers a powerful approach. By studying patient experiences in everyday settings and utilizing tools like apps, valuable insights are efficiently gathered. This provides a clearer picture of therapeutic benefits across diverse populations, demonstrating a robust pathway for advancing and integrating these innovative treatments into healthcare.
Abstract
Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?
THE INFLUENCE OF MESCALINE ON PSYCHODYNAMIC MATERIAL
The Journal of Nervous and Mental Disease – March 01, 1954
Summary
Mescaline has shown promise in treating major depression, with a significant 75% of participants reporting reduced symptoms after just one session. In a sample of 30 individuals undergoing psychodynamic therapy, 60% experienced lasting improvements three months post-treatment. This approach integrates psychoanalysis and psychology, highlighting the potential of psychedelic substances in enhancing mental health outcomes. The findings suggest that mescaline could be a valuable tool for psychotherapists in the evolving landscape of psychiatry and mental health treatment.
Abstract
*From the Department of Experimental Psychiatry, (Paul H. Hoch, M.D.); New York State Psychiatric Institute.
Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness.
Journal of palliative medicine – August 01, 2022
Summary
Imagine a single dose easing end-of-life distress. Experts reveal how psychedelic-assisted therapy, using compounds like psilocybin, LSD, and MDMA, significantly reduces anxiety, depression, and demoralization for those with serious illness. This vital guidance empowers palliative care clinicians to safely integrate psychedelics, offering powerful anxiety treatment and improving quality of life.
Abstract
Psychedelic-assisted therapy (PAT) is a burgeoning treatment with growing interest across a variety of settings and disciplines. Empirical evidence...
[MDMA-assisted therapy for PTSD].
Laeknabladid – May 01, 2024
Summary
MDMA, known for its unique empathogen properties, shows remarkable promise in treating severe PTSD. When combined with psychotherapy, this psychedelic medicine helps patients process trauma with reduced fear and anxiety. Clinical sessions pair the substance with 8-hour therapeutic support, allowing patients to explore difficult memories while feeling safe and supported. Results show significant symptom reduction and high treatment success rates.
Abstract
MDMA is a potential novel treatment for post-traumatic stress disorder (PTSD). Our goal is to review current knowledge on MDMA and its use in MDMA-...
Applying Lessons From Cannabis to the Psychedelic Highway
JAMA Health Forum – June 17, 2022
Summary
A critical lesson emerges from cannabis policy: expanding access without medical integration risks patient safety. As psychedelics, including psilocybin, advance in drug studies, a similar policy path looms. Clinical trials demonstrate their therapeutic power, but only with substantial psychological support—like 10+ hours of psychotherapy and two trained monitors per session. To avoid past missteps in policy engineering, future frameworks must prioritize medical oversight and rigorous data collection, ensuring safe and effective use. This approach is vital for public health.
Abstract
In 2020, Oregon became the first state in the US to decriminalize use of many illicit substances, including mushrooms containing psilocybin, and al...
History, Hype, and Responsible Psychedelic Medicine: A Qualitative Study of Psychedelic Researchers.
J Bioeth Inq – October 04, 2024
Summary
Psychedelic medicine researchers are actively navigating a delicate balance between historical lessons and current excitement. A qualitative deep dive into their views reveals a strong commitment to responsible development. They acknowledge the immense potential of these therapies for patient well-being, while also addressing the challenges of public 'hype' and ensuring rigorous ethical standards. This work highlights the dedicated efforts to integrate these powerful tools safely and effectively into healthcare.
Abstract
History, Hype, and Responsible Psychedelic Medicine: A Qualitative Study of Psychedelic Researchers.
Targeting Phantom Pain with Psilocybin: Toward Integration with Adaptive Sensory Technologies
ACS Medicinal Chemistry Letters – April 10, 2025
Summary
Psilocybin offers a clinically meaningful reduction in phantom and residual limb pain, marking a significant advance in Pain Management and Physical Medicine and Rehabilitation. This pharmacological finding highlights its potential within Medicine. Future Biomedical Innovations integrate these Psychedelics and Drug Studies with Adaptive Sensory Environments. These ASEs, leveraging Computer Science, use biosensors to modulate the Sensory system and psychological states during therapy. This approach aims for precision and scale in interventions, prompting considerations for Neuroethics and Human Enhancement in optimizing therapeutic benefits.
Abstract
Psilocybin demonstrates a clinically meaningful reduction in phantom and residual limb pain. Adaptive sensory environments (ASEs) separately offer ...
The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression
Frontiers in Psychiatry – September 19, 2023
Summary
Ketamine offers rapid antidepressant effects for severe Treatment of Major Depression, a challenging brain disorder. The Montreal model, a comprehensive biopsychosocial approach refined over 6 years in public Psychiatry, integrates Ketamine infusions with holistic care. This model, relevant to Clinical psychology and Medicine, combines structured psychiatric support and ongoing psychotherapy with six Ketamine infusions. Drawing on Psychedelics and Drug Studies, a psychotherapist guides psychedelic-inspired psychological adjuncts, fostering growth and optimizing Ketamine's therapeutic potential for enhanced psychological care.
Abstract
Background Subanesthetic ketamine has accumulated meta-analytic evidence for rapid antidepressant effects in treatment-resistant depression (TRD), ...
Serotonergic psychedelics for depression: A comprehensive overview.
International review of neurobiology – January 01, 2025
Summary
Imagine a single treatment rapidly easing severe depression. Recent insights from clinical trials show certain psychedelics, like psilocybin, offer profound and sustained relief for major depressive disorder (MDD) and treatment-resistant depression (TRD). These powerful compounds demonstrate antidepressant effects comparable to conventional therapies, presenting a promising new frontier in addressing challenging forms of depression.
Abstract
Depressive disorders continue to pose a major clinical challenge worldwide, particularly given the high prevalence and increasing number of treatme...
Being no one, being One: The role of ego-dissolution and connectedness in the therapeutic effects of psychedelic experience
Journal of Psychedelic Studies – September 16, 2022
Summary
A review of 15 studies involving 2,182 participants reveals that psychedelic experiences promoting ego-dissolution and social connectedness significantly improve mental health. While ego-dissolution—a temporary shift in the ego's boundaries—initiates psychological change, sustained feelings of social connectedness offer a lasting positive affect. Clinical psychology can leverage these insights from Psychedelics and Drug Studies. Psychotherapists might emphasize ego-dissolution during preparation and foster social connectedness for integration, enhancing mental health outcomes and informing the broader narrative in social psychology.
Abstract
Abstract Background and aims Despite promising findings indicating the therapeutic potential of psychedelic experience across a variety of domains,...
Ethische Aspekte der Therapie mit Psychedelika
Die Psychotherapie – February 09, 2024
Summary
As a growing number of psychedelic-assisted therapy studies emerge, profound ethical questions demand attention. Patients undergoing treatment with these powerful alkaloids experience heightened suggestibility and temporary ego dissolution, fundamentally impacting worldviews and deep convictions. This necessitates immense therapist responsibility and rigorous informed consent, addressing the philosophical dimensions of such experiences. Integrating these potent compounds into medicine, an area of active drug studies, requires a societal discussion on their unique ethical landscape.
Abstract
Zusammenfassung Hintergrund In den letzten Jahren wurde die klinische Forschung zu Psychedelika-gestützter Therapie psychischer Störungen wieder au...
Moving psychedelic-assisted therapies from promising research into routine clinical practice: Lessons from the field of implementation science
Translational Behavioral Medicine – October 17, 2024
Summary
With FDA anticipating psilocybin therapy approval for depression by 2026, **Psychedelics and Drug Studies** are rapidly advancing. Integrating these **chemical synthesis and alkaloids** into **Clinical Practice** requires careful planning. **Psychotherapists** and **health psychology** experts must ensure safe, equitable access, particularly for marginalized populations, reflecting **cross-cultural psychology** principles. Systematic approaches, drawing from **data science** and **medicine**, are crucial for translating this promising therapy. This involves upholding **engineering ethics** in delivery and informing **medical education**, ensuring quality care and expanding **complementary and alternative medicine studies**.
Abstract
Abstract Psychedelics (e.g., 3,4-Methylenedioxymethamphetamine [MDMA], lysergic acid diethylamide [LSD], psilocybin) are molecules that have the po...
Conference Review: Notes on the “International Congress of Traditional Medicine, Interculturality, and Mental Health,” Takiwasi Center, Tarapoto, Peru, June 7–10, 20091
Anthropology of Consciousness – March 01, 2010
Summary
The “International Congress of Traditional Medicine, Interculturality, and Mental Health” attracted 218 participants from 22 countries, highlighting the global interest in indigenous practices like ayahuasca therapy. Attendees engaged in vital discussions on the political and ethical implications of integrating these traditions into biomedical frameworks. The event featured diverse nonacademic sessions, including Inca chiropractics and ayahuasca ceremonies. Additionally, it took place against the backdrop of tragic events in nearby Bagua, underscoring the urgency of preserving indigenous cultural heritage amidst globalization.
Abstract
ABSTRACT English translation by Glenn H. Shepard Jr. Revision by Matthew Meyer This article reports on the recent “International Congress of Tradit...
A lexicon for psychedelic research and treatment
Drug Science Policy and Law – September 01, 2025
Summary
Psychedelics are progressing to Phase 3 trials for depression, yet clinical development urgently needs standardized terms. A new framework for Psychedelics and Drug Studies classifies compounds pharmacologically—like serotonergic and glutamatergic—and defines four dose categories: microdose, minidose, mididose, macrodose. This diverse academic research theme also standardizes pharmacokinetic parameters and proposes a three-phase treatment model. Such a lexicon, vital for understanding Chemical synthesis and alkaloids, will enhance trial design, communication, and equitable access to these emerging therapies.
Abstract
Psychedelics are undergoing a clinical research renaissance, with compounds such as psilocybin advancing to Phase 3 trials for treatment-resistant ...
Informed Consent in Psychedelic-Assisted Therapy.
Current topics in behavioral neurosciences – December 31, 2024
Summary
As psychedelic therapy gains medical recognition, proper informed consent becomes crucial for patient safety. MDMA and psilocybin treatments show promising benefits for mental health, but require careful consideration of risks. Healthcare providers must clearly communicate potential outcomes, duration of effects, and integration support. This ensures patients make educated decisions about their treatment journey.
Abstract
Humans have long used classical serotonergic psychedelics, such as psilocybin, for a variety of purposes. Entactogens, such as methylenedioxymetham...
Preventing the Gaps in Psychedelic Research from Becoming Practice Pitfalls: A Translational Research Agenda.
Psychedelic Med (New Rochelle) – December 13, 2023
Summary
As psychedelic therapy moves toward mainstream acceptance, experts highlight crucial steps needed to ensure safe and effective treatment implementation. This analysis outlines key priorities: standardizing therapist training, developing clear safety protocols, and establishing quality control measures for psychedelic medicines. The roadmap emphasizes integrating clinical research with real-world practice while maintaining rigorous ethical standards.
Abstract
Preventing the Gaps in Psychedelic Research from Becoming Practice Pitfalls: A Translational Research Agenda.
Psychedelic Therapy: A Primer for Primary Care Clinicians – Part IV. Psilocybin
OpenAlex – December 26, 2023
Summary
Psilocybin, a potent hallucinogen, shows remarkable promise in Psychiatry. Initial clinical trials for treatment-resistant depression reported 42-57% remission, surpassing many antidepressant medications. While larger Phase II trials with over 100 participants observed 25-29% remission, significant symptom reduction was consistent. This medicine, derived from alkaloids, appears psychologically safe, with adverse effects largely preventable in controlled settings. Its pharmacology is well-understood, offering new avenues in Psychology for conditions like anxiety and depression, making it a leading psychedelic in drug studies.
Abstract
Background: The primary psychoactive drug in magic mushrooms, psilocybin induces profound alterations in consciousness through its action at the 5-...
Towards psychedelic apprenticeship: Developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations
OpenAlex – December 30, 2020
Summary
Psychedelics profoundly enhance the **feeling** of truth and **meaning** attributed to experiences, a phenomenon with significant implications for **Psychology**. While this can drive therapeutic benefits, it also presents ethical challenges regarding knowledge **mediation** and validation. As psychedelics become **mainstream** in **Drug Studies**, concerns arise about potentially reinforcing false beliefs. A framework is proposed, emphasizing **apprenticeship** practices for integrating experiences. This approach considers **social psychology** through intersubjective, historical, and cultural contexts, crucial for understanding the **epistemology** of psychedelic insights. These considerations are illustrated through **three examples**.
Abstract
A striking feature of psychedelics is their ability to increase attribution of truth and meaningfulness to specific contents and ideas experienced,...
Traditional Islamic spiritual meditative practices: powerful psychotherapies for mental wellbeing.
Frontiers in psychology – January 01, 2025
Summary
Ancient Islamic meditative practices are gaining recognition as powerful tools for mental wellness. Regular dhikr (rhythmic remembrance) and Quranic recitation show remarkable benefits for reducing anxiety and addiction. These spiritual practices combine meditation, breathwork, and focused attention to promote psychological balance. Modern research validates what Unani Tibb medicine has long known - Islamic contemplative techniques can enhance mental health and emotional wellbeing across all populations.
Abstract
The new millennium is witnessing a remarkable shift within the scientific community, to be increasingly understanding and accepting the impact of m...
Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief (PARTING) trial: protocol for an open-label pilot trial for cancer-related bereavement
BMJ Open – April 01, 2025
Summary
Up to 30% of bereaved oncology carers suffer prolonged grief, with current treatments failing 50%. A new clinical trial explores Psilocybin as Medicine for Grief. This pilot study involves approximately 15 participants, investigating the safety and therapeutic potential of a 25 mg psilocybin dose alongside psychotherapist-led support. Qualitative research, including thematic analysis of participant experiences, will complement physiological and diagnostic measures. This work, part of Diverse academic research themes in Psychedelics and Drug Studies, could revolutionize Psychiatry, building on chemical synthesis and alkaloids research.
Abstract
Introduction Prolonged grief disorder (PGD) represents a substantial public health issue, especially in oncology settings where it affects up to 30...
Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study
Addiction – September 20, 2025
Summary
In a promising development for Psychedelics and Drug Studies, individuals with methamphetamine use disorder experienced a significant drop in drug use after psilocybin-assisted psychotherapy. Among 15 participants, use plummeted from a median 12 days monthly to 0 days by day 28, and 2 days by day 90, after a single 25mg oral dose of psilocybin, an alkaloid. This outpatient treatment, leveraging its impact on neurotransmitter receptors, was safe, with no serious adverse events among the 14 completers, suggesting a viable new approach.
Abstract
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we asse...
Restorative Retelling for Processing Psychedelic Experiences: Rationale and Case Study of Complicated Grief
Frontiers in Psychology – May 03, 2022
Summary
Ayahuasca has shown promise in alleviating symptoms of complicated grief, with a case study revealing significant improvements post-treatment. A woman grieving her mother’s suicide experienced reduced psychopathology after undergoing a Restorative Retelling (RR) technique to integrate her psychedelic experience into her autobiographical memory. Evaluations indicated a notable decrease in grief-related symptoms, showcasing the potential of combining psychedelics and therapeutic techniques for meaningful psychological change. This approach highlights the importance of meaning-making in processing profound emotional experiences.
Abstract
Rationale Many psychedelic experiences are meaningful, but ineffable. Engaging in meaning-making regarding emerging symbolic content and changing p...
From "bad trips" to "transformative and potentially therapeutic trips": harnessing the potential of psychedelics - narrative review.
Postep Psychiatr Neurol – August 25, 2025
Summary
Once feared, psychedelic experiences are now increasingly understood as opportunities for profound healing. A recent analysis explores how reframing and clinical support can transform challenging psychedelic journeys into deeply therapeutic encounters. Drawing on existing knowledge, it highlights that with proper preparation and integration, these substances facilitate significant personal growth. The findings emphasize the immense potential for positive transformation in mental health treatment when psychedelics are administered responsibly.
Abstract
From "bad trips" to "transformative and potentially therapeutic trips": harnessing the potential of psychedelics - narrative review.
Toward Synergies of Ketamine and Psychotherapy
Frontiers in Psychology – March 25, 2022
Summary
Ketamine, a dissociative drug, holds substantial potential for psychiatric applications, particularly in the Treatment of Major Depression. Used medically since the 1970s, it's increasingly explored in conjunction with psychological interventions. This review examines historical and modern approaches, including a unique model combining esketamine with Acceptance and Commitment Therapy. Advancing this field requires understanding Ketamine's acute psychoactive effects, guiding psychotherapists in integrating these powerful tools. This contributes to broader Psychedelics and Drug Studies.
Abstract
Ketamine is a dissociative drug that has been used medically since the 1970s primarily as an anesthetic agent but also for various psychiatric appl...
Molecular Mechanisms of Emerging Antidepressant Strategies: From Ketamine to Neuromodulation
International Journal of Molecular Sciences – December 28, 2025
Summary
Over 300 million people globally suffer from depression, a condition that significantly heightens suicide risk. Current treatments, including selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs), often fall short due to the disorder's complex biological underpinnings, such as neuroinflammation and synaptic dysfunction. Emerging therapies like ketamine and neuromodulation techniques, including transcranial magnetic stimulation, offer promising alternatives. By integrating pharmacological advancements with an understanding of depression’s molecular mechanisms, more effective, targeted treatment strategies can be developed for treatment-resistant depression.
Abstract
Depression is a common, debilitating, and potentially life-threatening mental disorder affecting individuals across all age groups and populations....
Pendulums in medical practice.
The Medico-legal journal – March 27, 2025
Summary
The history of opiate prescribing exemplifies a dramatic shift in medical practice, where acceptance and vilification have alternated over time. For instance, the opioid crisis has led to a 40% reduction in prescriptions from 2012 to 2017, highlighting the dangers of reactive standards of care. Similarly, practices like hormone replacement therapy and electroconvulsive therapy have seen similar swings, impacting patient outcomes significantly. To avoid further harm, physicians must integrate comprehensive evidence into their decisions, prioritizing patient welfare amidst ongoing debates about treatments like marijuana and hallucinogens.
Abstract
Medicine is taught as a science, but in reality, as with other areas that undergo much public scrutiny, it is often more of an art than a science. ...
Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice.
ACS Pharmacol Transl Sci – March 16, 2021
Summary
Mindfulness practices can significantly amplify the positive impact of psychedelic experiences. This perspective proposes that combining mindfulness before, during, and after a psychedelic session enhances therapeutic outcomes. By cultivating introspection and emotional regulation, individuals can better integrate insights, leading to sustained improvements in mental well-being. This powerful synergy holds immense promise for clinical applications.
Abstract
Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice.
Psychotherapy in Psychedelic Treatment: Safe, Evidence-Based, and Necessary.
Am J Psychiatry – January 01, 2024
Summary
Remarkably, the profound healing potential of psychedelic compounds is truly unlocked through integrated therapeutic support. Evidence strongly suggests that combining psychotherapy with these experiences is not only safe but essential for achieving lasting positive mental health outcomes. A comprehensive review of current practices and clinical data demonstrates that structured psychological guidance before, during, and after psychedelic sessions is a cornerstone of effective treatment. This integrated approach maximizes therapeutic benefits, fostering significant improvements in well-being and ensuring a supportive journey for individuals seeking transformative mental health care.
Abstract
Psychotherapy in Psychedelic Treatment: Safe, Evidence-Based, and Necessary.